Prudential Financial
LENZ

Prudential Financial’s LENZ Therapeutics LENZ Stock Holding History

Prudential Financial’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,435
Closed -$215K – 2810
2024
Q2 		$215K Buy
+12,435
New +$217K ﹤0.01% 2464

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Prudential Financial's LENZ Position: Q3 2024 in Review

Prudential Financial sold out of LENZ Therapeutics (LENZ) in Q3 2024, closing a stake of 12,435 shares — an estimated $215K sold.

Prudential Financial first reported a position in LENZ in Q2 2024 and held it in 1 quarter. The position peaked at $215K in Q2 2024. 78 funds tracked by Wall St. Rank hold LENZ as of Q3 2024.

  • Prudential Financial reported no remaining LENZ Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Prudential Financial sold 12,435 LENZ Therapeutics shares in Q3 2024, an estimated $215K.
  • Prudential Financial first reported a position in LENZ Therapeutics in Q2 2024 and held it in 1 quarter.
  • Prudential Financial's LENZ Therapeutics position peaked at $215K in Q2 2024.
  • 78 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2024.

Based on Prudential Financial's 13F filing for Q3 2024, filed 14 Nov 2024.